



The Brazilian Journal of INFECTIOUS DISEASES

www.elsevier.com/locate/bjid



Original article

Prevalence of *Chlamydia trachomatis* and *Neisseria gonorrhoea* and associated factors among women living with Human Immunodeficiency Virus in Brazil: a multicenter study

Angelica E. Miranda^{a,*}, Mariangela F. Silveira^b, Ana Gabriela Travassos^c, Teresinha Tenório^d, Isabel Cristina Chulvis do Val^e, Leonor de Lannoy^f, Hortensio Simões de Mattos Junior^g, Newton Sergio de Carvalho^h

^a Universidade Federal do Espírito Santo, Vitória, ES, Brazil

^b Universidade Federal de Pelotas, Pelotas, RS, Brazil

^c Universidade Estadual da Bahia, Salvador, BA, Brazil

^d Universidade Federal de Pernambuco, Recife, PE, Brazil

^e Universidade Federal Fluminense, Niterói, RJ, Brazil

^f Unidade de Saúde Mista da Asa Sul, Brasília, DF, Brazil

^g Laboratório São Marcos, Vila Velha, ES, Brazil

^h Universidade Federal do Paraná, Curitiba, PR, Brazil

ARTICLE INFO

Article history:

Received 17 October 2016

Accepted 17 March 2017

Available online 18 May 2017

Keywords:

Chlamydia trachomatis

Neisseria gonorrhoeae

HIV

Women

Brazil

ABSTRACT

Background: *Chlamydia trachomatis* (CT) and *Neisseria gonorrhoeae* (GC) cause infections in the female genital tract, increasing susceptibility to and infectiousness of HIV. The objectives of the present study were to determine the prevalence and associated factors of CT and GC infection among HIV-infected women in Brazil.

Methods: Cross-sectional study conducted from March to December 2015, including HIV-infected women attending referral centers in nine states of Brazil, aged 18–49 years, nonpregnant. An interview was conducted including socio-demographic, epidemiological and clinical characteristics. After the interview, gynecological examination was conducted to collect cervical cytology and vaginal secretion to *C. trachomatis* and *N. gonorrhoeae* tests through molecular biology.

Results: A total of 802 (89.1%) women participated. The prevalence of CT was 2.1% (17/802) and CG was 0.9% (7/802). The prevalence of a positive test for both CT and/or GC was 2.7%. The factors associated with positive CT/GC test in the multivariate logistic regression analysis were abnormal Papanicolaou smear (OR 4.1; 95% CI: 1.54–11.09) and the presence of abnormal

* Corresponding author.

E-mail address: amiranda.ufes@gmail.com (A.E. Miranda).

<http://dx.doi.org/10.1016/j.bjid.2017.03.014>

1413-8670/© 2017 Sociedade Brasileira de Infectologia. Published by Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).



CrossMark

cervical discharge (OR 2.6; 95% CI: 1.02–6.71). Among 377 women who reported previous STI 245 (65.0%) reported using condom more frequently after being diagnosed. 62 (16.4%) discovered the STI after the partner told he was infected; 157 (41.6%) had STI symptoms and looked for care, and 158 (41.9%) discovered it in a routine consultation for another reason.

Conclusions: The control of STI represents a unique opportunity to improve reproductive health of women living with HIV. STI diagnosis can change their behavior and reduce the sexual transmission of HIV and bacterial STI.

© 2017 Sociedade Brasileira de Infectologia. Published by Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Chlamydia trachomatis (CT) and *Neisseria gonorrhoeae* (GC) screening can prevent health complications. Infection in the lower genital tract can result in upper genital tract complications, such as pelvic inflammatory diseases, ectopic pregnancy, chronic pelvic pain, and infertility in asymptomatic women, and transmission of infection during pregnancy and labor.^{1,2} They also increase susceptibility and infectiousness of HIV infection.³

In HIV-infected women, infection with CT or GC is an important biologic marker of behavior that may expose others to HIV. Furthermore, CT and GC are associated with increased cervico-vaginal HIV shedding that may increase HIV transmissibility.⁴ Identification of HIV-infected women with CT or GC can help target preventive interventions such as promoting safer sexual practices. Treatment of sexually transmitted infections (STI) also may impact heterosexual HIV transmission.⁵

Previous studies from Brazil reported prevalence rates of 3.0% of CT and 0.9% of GC among HIV-infected women in Rio de Janeiro⁶ and in Manaus a rate of CT of 4.3%.⁷ These results were not different from data reported in Zambia that found a prevalence rate of 1% of CT and 1.4% of GC in HIV-infected women.^{8,9}

The aim of the current study was to determine the prevalence of and associated factors for CT and GC among HIV-infected women attending referral care centers for HIV/AIDS in Brazil.

Methods

A cross-sectional study was conducted among women living with HIV/AIDS who attended referral care centers for HIV/AIDS in nine different Brazilian states: Amazonas, Pernambuco, Bahia, Federal District, Espírito Santo, Rio de Janeiro, São Paulo, Paraná, and Rio Grande do Sul, distributed in the five geographical regions of Brazil, from March through December 2015.

Nonpregnant women aged 18–49 years, with a positive result for HIV infection, being cared for at the gynecology service linked to reference hospitals, who accepted to participate were invited to take part in the study.

A 20-min face-to-face interview was conducted using a standardized questionnaire (validated in a pilot study) that included socio-demographic characteristics (age, education, marital status, family income, place of residence); epidemiological (smoking, use of alcohol and illicit drugs, use of condoms, number of sexual partners, sexual practices) and clinical (vaginal discharge, previous STI, stage of infection with HIV, CD4 cell count and HIV viral load). A pilot study was conducted in a small number of women living with HIV/AIDS to evaluate the reliability and validity of the questionnaire.

After the interview, gynecological examination was carried out to collect cervical cytology and vaginal/cervical secretion to test for CT and GC through molecular biology. Samples were analyzed in an automated system for real time PCR (COBAS 4800 CT/NG – Roche Molecular Systems, Branchburg, NJ) for detection of CT and GC, as per the manufacturer's instructions at the Molecular Biology Laboratory of the Infectious Diseases Unit of the Federal University of Espírito Santo and São Marcos Laboratory, a ISO 9001:2000 (INMETRO) and UKAS (England) certified private laboratory in Vila Velha (ES). Endocervical samples were collected using swabs, PreservCyt transport medium and stored at 10 °C until their transportation at low temperature to the reference laboratory, in a period of seven to 10 days.

Selection of the study sample took into account the proportion of AIDS cases from the five geographical regions reported to the AIDS National Information Surveillance System in 2010 (consolidated with the Information Surveillance System for Mortality, laboratory tests – CD4 counts and HIV viral load, and antiretroviral therapy). A total of 12,845 HIV-infected women were reported: 9.7% from the North; 20.1% from the Northeast; 38.6% from the Southeast; 25.2% from the South, and 6.4% from the Midwest region. Based on these criteria nine clinics were included: one in Northern region, two in the Northeast, three in the Southeast, two in the Southern region, and one in the Midwest region.

The sample size was calculated to estimate the prevalence of CT and GC in women living with HIV/AIDS, with a 95% confidence interval (CI) bilateral size of 0.5%. It was assumed as the lowest expected frequency 0.9% of *N. gonorrhoeae* in women living with HIV/AIDS⁶; accepting a variation of $\pm 0.3\%$ a number of 773 women were necessary. Allowing for a loss of 10%, a final sample of 850 women distributed proportionally in each clinic 95 women per clinic were to be included.

Table 1 – Demographic and behavior characteristics by CT/GC positivity among women living with HIV in Brazil, 2015 (N = 802).

Variable	Total N (%)	CT/GC+ N (%)	CT/GC– N (%)	OR (95% CI) p value
Age (years)				
≤24	43 (5.4)	03 (7.0)	40 (93.0)	2.9 (0.83–10.28)
>24	759 (94.6)	19 (2.5)	740 (97.5)	1
Education (years)				
≤8	398 (49.6)	08 (2.1)	390 (97.9)	0.6 (0.24–1.38)
>8	404 (50.4)	14 (3.5)	390 (96.5)	1
Marital status				
Single/Divorced/Widow	396 (49.4)	12 (3.0)	384 (97.0)	1.2 (0.53–2.90)
Married/living together	406 (50.6)	10 (2.5)	396 (97.5)	1
First sex intercourse				
≤15 years	299 (37.3)	11 (3.7)	288 (96.3)	1.7 (0.73–3.99)
≥16 years	503 (62.7)	11 (2.2)	492 (97.8)	1
Number of partners (life)				
Only one	67 (8.4)	01 (1.5)	66 (98.5)	1
2–5	490 (61.1)	15 (3.1)	475 (96.9)	1.0 (0.56–1.89)
6–9	79 (9.9)	02 (2.5)	77 (97.5)	1.2 (0.85–1.83)
≥10	166 (20.7)	04 (2.4)	162 (97.6)	1.4 (0.76–2.53)
Tobacco use				
Yes	157 (19.6)	06 (3.8)	151 (96.2)	1.6 (0.60–4.06)
No	645 (80.4)	16 (2.5)	629 (97.5)	1
Illicit drug abuse				
Yes	150 (18.7)	06 (4.0)	144 (96.0)	1.7 (0.64–4.31)
No	652 (81.3)	16 (2.5)	636 (97.5)	1
Injecting drug use				
Yes	19 (2.4)	01 (5.3)	18 (94.7)	2.0 (0.26–15.81)
No	783 (97.3)	21 (2.7)	762 (97.3)	1
Consistent Condom use				
No	227 (28.3)	06 (2.6)	221 (97.4)	0.9 (0.36–2.45)
Yes	575 (71.7)	16 (2.8)	559 (97.2)	1
Anal sex				
Yes	350 (43.6)	13 (3.7)	337 (96.3)	1.9 (0.80–4.50)
No	452 (56.4)	09 (2.0)	443 (98.0)	1

Data were analyzed using the SPSS – data entry statistical program (Statistical Package for the Social Sciences) version 17.0. A preliminary analysis was performed using exploratory techniques on the data, to check the distribution patterns and trends of the variables. Univariate analysis was then performed to check for the presence of association between the variables. Chi-square tests were used to compare proportions and Student's t tests and variance analysis were used for testing differences between mean values. Univariate and multivariate odds ratios (ORs) (adjusted for potential confounders) and 95% CIs were reported. Variables that were significant at $p < 0.15$ in univariate analysis and known confounders (e.g., age and education) were considered in the multivariate analysis using a stepwise multiple logistic regression model.

This project was submitted to and approved by the Research Ethics Committee (#131107/2012) of Center for Health Sciences of the Federal University of Espírito Santo. All selected women were invited to take part voluntarily in the study and those who accepted signed a written consent form. Those who were diagnosed as being infected by CT or GC received treatment as recommended by the Brazilian Ministry of Health guidelines.

Results

Out of 850 eligible women 802 (94.4%) accepted to participate in the study, from March to December 2015. Median age was 39 (IQR 34–46) years and median years of education was 9 (IQR 6–11). The prevalence of CT was 2.1% (17/802) and of CG 0.9% (7/802). The prevalence of a positive test for CT and/or GC was 2.7% (22 cases).

The prevalence rates by geographical region were: North 2.6%; Northeast 2.6%; Midwest 1.2%; Southeast 3.5%, and South 2.4%. There was no statistically significant difference between the geographical regions.

Table 1 shows demographic and behavior characteristics of women living with HIV in Brazil. None of the variables was associated to CT/GC positive test. A total of 43 (5.4%) women was younger than 25 years old, 299 (37.3%) had the first intercourse before 16 years, and 575 (71.7%) reported consistent condom use.

Clinical characteristics are described in **Table 2**. A total of 137 (17.1%) reported pelvic pain. Abnormal cervical discharge (5.7% vs. 1.7%, $p = 0.002$); abnormal Papanicolaou smear (9.9%

Table 2 – Clinical characteristics by CT/GC positivity among women living with HIV in Brazil, 2015 (N = 802).

Variable	Total N (%)	CT/GC+ N (%)	CT/GC– N (%)	OR (95% CI) p value
Previous STI				
Yes	377 (47.0)	10 (2.7)	367 (97.3)	0.9 (0.40–2.20)
No	425 (53.0)	12 (2.8)	413 (97.2)	1
Previous miscarriage				
Yes	171 (21.3)	5 (2.9)	166 (97.1)	1.1 (0.40–2.99)
No	631 (78.7)	17 (2.7)	614 (97.3)	1
Pelvic pain				
Yes	137 (17.1)	6 (4.4)	131 (95.6)	1.9 (0.71–4.83)
No	665 (82.9)	16 (2.4)	649 (97.6)	1
Cervical discharge				
Yes	212 (26.4)	12 (5.7)	200 (94.3)	3.5 (1.48–8.20)
No	590 (73.6)	10 (1.7)	580 (98.3)	1
Cystitis				
Yes	116 (14.5)	4 (3.4)	112 (96.6)	1.3 (0.44–3.98)
No	686 (85.5)	18 (2.6)	668 (97.4)	1
Genital ulcer				
Yes	52 (6.5)	1 (1.9)	51 (98.1)	1.5 (0.19–11/14)
No	750 (93.5)	21 (2.8)	729 (97.2)	1
Genital Lymphadenopathy				
Yes	26 (3.2)	2 (7.7)	24 (92.3)	3.2 (0.70–14.29)
No	776 (96.8)	20 (2.6)	756 (97.4)	1
Genital Itching				
Yes	142 (17.7)	7 (4.9)	135 (95.1)	2.2 (0.89–5.59)
No	660 (82.3)	15 (2.3)	645 (97.7)	1
TARV use				
Yes	718 (89.5)	20 (2.8)	698 (97.2)	0.9 (0.20–3.70)
No	84 (10.5)	2 (2.4)	82 (97.6)	1
CD4 Count				
≥500	508 (63.3)	15 (3.0)	493 (97.0)	0.8 (0.32–1.99)
≤499	294 (36.7)	7 (2.4)	287 (97.6)	1
Papanicolaou smear				
Abnormal	71 (8.9)	7 (9.9)	64 (90.1)	5.2 (2.05–13.27)
Normal	731 (91.1)	15 (2.1)	716 (97.9)	1
Viral load				
Detectable	212 (26.4)	10 (4.7)	202 (95.3)	2.3 (1.01–5.60)
Undetectable	590 (73.6)	12 (2.0)	578 (98.0)	1

Table 3 – Multivariate analysis of factors associated with CT/GC positivity among women living with HIV in Brazil, 2015.

Variables	OR	(95% CI)	p-value
Age in years (Up to 24 vs. ≥25)	2.6	(0.71–9.63)	0.148
Anal sex (Yes vs. No)	1.5	(0.62–3.70)	0.361
Papanicolaou smear (Abnormal vs. normal)	4.1	(1.54–11.09)	0.005
Pelvic pain (Yes vs. No)	1.3	(0.28–2.24)	0.656
Cervical discharge (Yes vs. No)	2.6	(1.02–6.71)	0.046
Genital Itching (Yes vs. No)	1.1	(0.40–3.20)	0.820
Genital Lymphadenopathy (Yes vs. No)	1.5	(0.27–7.94)	0.662
Viral load (Detectable vs. Undetectable)	1.7	(0.67–4.06)	0.274

Hosmer and Lemeshow test: $\chi^2 = 6.367$, df: 7, $p = 0.498$.The variables in bold were statistically significant. They presented a p value <0.05.

vs. 2.1%, $p < 0.001$), and detectable HIV viral load (4.7% vs. 2.0%, $p = 0.040$) were associated with a positive CT/GC test result.

The factors associated with a positive CT/GC test in the multivariate logistic regression analysis were abnormal Papanicolaou smear (OR 4.1; 95% CI: 1.54–11.09) and the

presence of abnormal cervical discharge (OR = 2.6; 95% CI: 1.02–6.71) (Table 3).

Table 4 shows subanalyses performed in 377 women who reported previous STI. A total of 245 (65.0%) reported using condom more frequently after receiving the diagnosis of STI.

Table 4 – Health behavior of women living with HIV in Brazil after receiving an STI diagnosis, by condom use, 2015 (N = 377).

Variables	Condom use N (%)	No condom use N (%)	p-value
<i>How did you discover the STI?</i>			0.043
Partner told you he was infected by an STI	38 (61.3)	24 (38.7)	
You had STI symptoms and looked for care	116 (73.9)	41 (26.1)	
You discovered it in a routine consultation for another reason	123 (77.8)	35 (22.2)	
<i>When you were diagnosed with an STI, where did you treat it?</i>			0.713
I did not treat	5 (62.5)	3 (37.5)	
Primary Health Unit	165 (72.1)	64 (27.9)	
Pharmacy	7 (77.8)	2 (22.2)	
STI clinic	100 (73.5)	31 (23.7)	
<i>Did you tell your partner about the STI diagnosis?</i>			0.155
Yes	201 (75.6)	65 (24.4)	
No	76 (68.5)	35 (31.5)	
<i>After receiving the diagnosis did you use condoms more often?</i>			0.001
Yes	207 (84.5)	38 (15.5)	
No	70 (53.0)	62 (47.0)	
<i>After receiving the diagnosis you did you decrease your sexual activity?</i>			0.331
Yes	132 (75.9)	42 (24.1)	
No	145 (71.4)	58 (28.6)	

Sixty-two (16.4%) discovered the STI after the partner told he was infected by an STI; 157 (41.6%) had STI symptoms and looked for care, and 158 (41.9%) discovered the STI in a routine consultation for another reason.

Discussion

The prevalence of CT and GC in HIV-infected women in Brazil was lower than the rates reported among adolescents or young pregnant women.^{10,11} These results are in agreement with previous studies conducted in Rio de Janeiro⁶ and Manaus⁷ and a little higher compared to HIV-infected women from Zambia.⁸ The observed lower rates could be attributed to the older age of these women compared to pregnant women or adolescents.^{2,10,11} Due to their HIV status, it is possible that these participants were more likely to be receiving ongoing medical care and antibiotics prescriptions. These results can suggest that engaging in HIV care may play a role for controlling STI in this population.

The factors associated with positive CT/GC test in the final multivariate model were abnormal Papanicolaou smear and presence of abnormal cervical discharge, which does not include inflammatory results, according with the Bethesda system.¹² Some studies have linked the presence of Chlamydia in women with HPV infection and abnormal Pap smears in the general population.¹³ In 2011 Lehtinen et al. published a cohort study showing that women with CT at baseline were 1.78 times more likely to develop cervical intraepithelial neoplasia grade 2 due any HPV type, than those without CT.¹⁴ Screening for cervical asymptomatic CT and GC can identify women who need follow-up for HPV infection and more careful investigation of precursor lesions of cervical cancer. The association between vaginal discharge and CT and GC infection, described in our study, was not commonly reported in previous studies.^{15,16} The syndromic management of genital infections has not been

considered effective, with this symptom being a poor predictor of cervicitis by CT and GC. Therefore, screening of asymptomatic women remains the best suited recommendation for this target population.¹⁵

Women who have reported a previous STI diagnosis were questioned about how they found out the STI. Almost half of them received treatment because they had STI symptoms and looked for care or discovered the STI in a routine consultation for another reason. The control of STI represents a unique opportunity to improve reproductive health of women living with HIV.⁵ Both ulcerative and non-ulcerative STI increase the risk of HIV transmission by three to 10 times, depending on the type and etiology of the STI.⁵ HIV-infected individuals affected by an STI have increased HIV viral load in genital secretions,^{4,17} thereby increasing considerably their potential of infectiousness and transmission.

The risk of HIV sexual transmission is different according to the sexual relationship. Female-to-male transmission have a risk of 0.04–0.38% per sexual act, increasing to 5.3% in case of previous history or presence of STI and genital ulcer.¹⁸ Sexual behavior has been modified worldwide, with more new sexual practices, low use of condom, and low concern about the risk of STI transmission.¹⁹ In our study, we identified that only 41.6% of the women had the diagnosis of STI because they looked for care due to presence of related symptoms. The knowledge of this diagnosis led to increased use of condoms during sexual relations. The access to STI diagnosis brings effective prevention and can change sexual behavior.

Although a cross-sectional study is not ideal for determining risk factors, its application is justified. Knowing CT and GC prevalence rates and its associated factors in HIV-infected women is important to demonstrate their susceptibility to complications caused by these infections. Given the low prevalence of some risk factors in this sample, it is possible that the number of studied women was not sufficient to find statistical association between some independent variables and CT/GC

positivity. The possibility of biased answers cannot be ruled out because of the general tendency to give socially acceptable replies in face-to-face interviews.

Despite the limitations, this study suggests that screening programs must be cost-effective and must be made acceptable to patients by using non-invasive procedures. It could also be considered a preventive measure aimed to determine risk factors, or detect and treat abnormal signal and symptoms that could later cause complications. After the “Treat as Prevention” strategy, adopted in Brazil since 2013,²⁰ people used condom less frequently, because assumed HIV could not be transmitted in the presence of viral suppression.²¹ At the same time, worldwide, bacterial STI, such as syphilis, CT, and NG are a high burden, mainly in people living with HIV.²² Controlling STI and identifying factors associated with such diseases continues to be an important element in the design of interventions targeting STI and as a result, HIV prevention in Brazil.

Financial support

Technical cooperation agreement – Brazilian Department of STI, AIDS and viral hepatitis, Ministry of Health and United Nations office for drugs and crime. Project BRA/K57, process #01/2013.

Conflicts of interest

The authors declare no conflicts of interest.

REFERENCES

1. Holmes KK, Sparling PF, Stamm WE, et al. In: Holmes KK, Sparling PF, Stamm WE, Piot P, Wasserheit JN, editors. Sexually transmitted diseases. New York: McGraw-Hill; 2008.
2. Rours GI, Duijts L, Moll HA, et al. *Chlamydia trachomatis* infection during pregnancy associated with preterm delivery: a population-based prospective cohort study. *Eur J Epidemiol.* 2011;26:493–502.
3. Cohen MS, Hoffman IF, Royce RA, et al. Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. *Lancet.* 1997;349:1868–73.
4. Ghys PD, Fransen K, Diallo MO, et al. The associations between cervicovaginal HIV shedding, sexually transmitted diseases and immunosuppression in female sex workers in Abidjan, Côte d'Ivoire. *AIDS.* 1997;11:F85–93.
5. Wasserheit JN. Epidemiological synergy: interrelationships between human immunodeficiency virus infection and other sexually transmitted diseases. *Sex Transm Dis.* 1992;19:61–77.
6. Grinsztejn B, Bastos FI, Veloso VG, et al. Assessing sexually transmitted infections in a cohort of women living with HIV/AIDS, in Rio de Janeiro, Brazil. *Int J STD AIDS.* 2006;17:473–8.
7. Silva LCF, Miranda AE, Batalha RS, et al. *Chlamydia trachomatis* infection among HIV-infected women attending an AIDS clinic in the city of Manaus, Brazil. *Braz J Infect Dis.* 2012;16:335–8.
8. Alcaide ML, Jones DL, Chitalu N, Weiss S. *Chlamydia* and Gonorrhea infections in HIV-positive women in Urban Lusaka, Zambia. *J Glob Infect Dis.* 2012;4:141–4.
9. Pinto VM, Tancredi MV, Silva RJC, et al. Prevalence and factors associated with *Chlamydia trachomatis* infection among women with HIV in São Paulo. *Rev Soc Bras Med Trop.* 2016;49:312–8.
10. Pinto V, Szwarcwald C, Baroni C, et al. *Chlamydia trachomatis* prevalence and risk behaviors in parturient women aged 15 to 24 in Brazil. *Sex Transm Dis.* 2011;38:957–61.
11. Travassos AGA, Brites C, Netto EM, et al. Prevalence of sexually transmitted infections among HIV-infected women in Brazil. *Braz J Infect Dis.* 2012;16:581–5.
12. Apgar BS, Zoschnick L, Wright TC. The 2001 Bethesda System terminology. *Am Fam Physician.* 2003;68:1992–8.
13. Silins I, Ryd W, Strand A, et al. *Chlamydia trachomatis* infection and persistence of human papillomavirus. *Int J Cancer.* 2005;116:110–5.
14. Lehtinen M, Ault KA, Lyytikainen E, et al. *Chlamydia trachomatis* infection and risk of cervical intraepithelial neoplasia. *Sex Transm Infect.* 2011;87:372–6.
15. Mlisana K, Naicker N, Werner L, et al. Symptomatic vaginal discharge is a poor predictor of sexually transmitted infections and genital tract inflammation in high-risk women in South Africa. *J Infect Dis.* 2012;206:6–14.
16. Djomand G, Gao H, Singa B, et al. Genital infections and syndromic diagnosis among HIV-infected women in HIV care programmes in Kenya. *Int J STD AIDS.* 2016;27:19–24.
17. Gray RH, Wawer MJ, Brookmeyer R, et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. *Lancet.* 2001;357:1149–53.
18. Boily MC, Baggaley RF, Wang L, et al. Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. *Lancet Infect Dis.* 2009;9:118–29.
19. Owen BN, Brock PM, Butler AR, et al. Prevalence and frequency of heterosexual anal intercourse among young people: a systematic review and meta-analysis. *AIDS Behav.* 2015;19:1338–60.
20. Brasil. Ministério da Saúde Secretaria de Vigilância em Saúde, Departamento de DST A e HV. Protocolo Clínico e Diretrizes Terapêuticas para manejo da infecção pelo HIV em adultos; 2013. At <http://www.aids.gov.br/sites/default/files/anexos/publicacao/2013/55308/protocolofinal.31.7.2015.pdf.31327.pdf> [accessed 23.07.16].
21. Golub SA, Kowalczyk W, Weinberger CL, Parsons JT. Preeexposure prophylaxis and predicted condom use among high-risk men who have sex with men. *J Acquir Immune Defic Syndr.* 2010;54:548–55.
22. Newman L, Rowley J, Vander Hoorn S, et al. Global estimates of the prevalence and incidence of four curable sexually transmitted infections in 2012 based on systematic review and global reporting. *PLOS ONE.* 2015;10:e0143304 [review].